PIETRASANTA, DANIELA
 Distribuzione geografica
Continente #
EU - Europa 210
NA - Nord America 173
AS - Asia 130
SA - Sud America 19
AF - Africa 1
Totale 533
Nazione #
US - Stati Uniti d'America 161
RU - Federazione Russa 65
SG - Singapore 56
IE - Irlanda 46
DE - Germania 25
SE - Svezia 23
CN - Cina 20
BR - Brasile 17
VN - Vietnam 17
FR - Francia 16
HK - Hong Kong 15
GB - Regno Unito 8
IT - Italia 7
CZ - Repubblica Ceca 5
MX - Messico 5
PL - Polonia 5
BD - Bangladesh 4
CA - Canada 4
IN - India 4
AT - Austria 3
JP - Giappone 3
FI - Finlandia 2
IQ - Iraq 2
LT - Lituania 2
MY - Malesia 2
OM - Oman 2
BO - Bolivia 1
CO - Colombia 1
CR - Costa Rica 1
DO - Repubblica Dominicana 1
ES - Italia 1
GR - Grecia 1
IL - Israele 1
JM - Giamaica 1
KG - Kirghizistan 1
KZ - Kazakistan 1
SI - Slovenia 1
TR - Turchia 1
UZ - Uzbekistan 1
ZA - Sudafrica 1
Totale 533
Città #
Dublin 46
San Jose 23
Singapore 23
Ashburn 19
Hong Kong 15
Beijing 9
Chandler 9
Boardman 7
Lauterbourg 7
Bremen 6
Lawrence 6
Los Angeles 6
Moscow 6
Munich 6
Princeton 6
Brno 5
Frankfurt am Main 5
Ho Chi Minh City 5
New York 5
Santa Clara 5
Hanoi 4
Hillsboro 4
Somaglia 4
São Paulo 4
Warsaw 4
Buffalo 3
Chennai 3
Chicago 3
Orem 3
Ottawa 3
Tokyo 3
Bexley 2
Curitiba 2
Gunzenhausen 2
Helsinki 2
Manchester 2
Mexico City 2
Nuremberg 2
Poplar 2
Querétaro 2
Redondo Beach 2
Seattle 2
Vienna 2
Ankara 1
Anápolis 1
Athens 1
Atlanta 1
Baghdad 1
Brooklyn 1
Cagliari 1
Cahors 1
Campo Alegre de Lourdes 1
Charleston 1
Chittagong 1
Conceição do Mato Dentro 1
Delhi 1
Denver 1
Dover 1
Embu das Artes 1
Falkenstein 1
Fowlerville 1
Guarulhos 1
Jacobina 1
Johannesburg 1
Kingston 1
Kirkuk 1
Kuala Lumpur 1
La Paz 1
Lauro de Freitas 1
Ljubljana 1
London 1
Marseille 1
Medellín 1
Miami 1
Monterrey 1
Muscat 1
Osasco 1
Palermo 1
Petaling Jaya 1
Phủ Lý 1
Rio de Janeiro 1
San Francisco 1
San José 1
Seeb 1
São José do Belmonte 1
Talas 1
Taldykorgan 1
Tashkent 1
Thái Bình 1
Toronto 1
Treze Tílias 1
Vilnius 1
Wroclaw 1
Totale 331
Nome #
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study 89
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials 84
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases 84
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases 80
Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group 78
Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study 76
Efficacy of front‐line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter “Real‐World” study 49
Totale 540
Categoria #
all - tutte 3.228
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.228


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202218 0 0 0 0 0 0 0 0 0 0 6 12
2022/2023107 6 6 10 0 7 7 0 12 50 1 3 5
2023/202435 4 1 3 0 3 0 10 0 0 0 3 11
2024/202582 5 0 6 1 6 4 2 18 20 2 7 11
2025/2026298 18 11 20 42 49 27 39 49 19 24 0 0
Totale 540